Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03705663 · ClinicalTrials.gov registry record
Identification of the Pre-exposure Prophylaxis (PrEP) Cascade for Women.
A clinical trial, sponsored by Medstar Health Research Institute.
- Completed
- Registry status
- 25
- Enrollment target
NCT03705663: Completed study, sponsored by Medstar Health Research Institute.
NCT03705663 is a clinical trial that has completed, run by Medstar Health Research Institute. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03705663 has completed, sponsored by Medstar Health Research Institute.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
Pre-exposure prophylaxis (PrEP) is a daily pill that greatly reduces the risk of transmission of human immunodeficiency virus (HIV), however the barriers to PrEP use for women are understudied and PrEP is underutilized by women. Partnering with the DC Department of Health and the DC Center for AIDS Research (DC-CFAR), the overarching goals are (1) to identify and populate the PrEP cascade for women, (2) to provide a blueprint for family planning providers to integrate HIV prevention into their practices and target evidence-based interventions to the women at highest risk for HIV in their communities, and (3) to evaluate the cost-effectiveness of this intervention. The overarching hypotheses are that (1) the timeline and roadmap to PrEP adoption and the PrEP cascade will be different for cis-gender women than that described for men who have sex with men (MSM) and transgender women, (2) women seeking family planning services will be eligible for and interested in PrEP and family planning providers are ideally situated to provide this care, and (3) provision of PrEP in the family planning setting will be cost-effective. This research proposes to evaluate (1) PrEP cascade of events for women (eligibility for PrEP, acceptability/interest in PrEP, access/linkage to a PrEP program, initiation of PrEP, retention, and adherence to PrEP) and (2) the integration of universal screening for PrEP and PrEP provision into a women's family planning clinic. This research will allow for targeted evidence-based interventions to reach women at high-risk for HIV and will provide a blueprint for the implementation of PrEP services in the family planning setting nationally.
Primary Outcome
We will be using a variety of measures to describe the "PrEP cascade" for women, specifically the proportion of women who initiate, continue, and adhere to PrEP and the timeline associated with the steps of the PrEP cascade.
Interventions
- BEHAVIORAL PrEP initiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2020-04-27 |
What the finished NCT03705663 record still lists
NCT03705663 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which PrEP initiation is the first listed.
NCT03705663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03705663 about?
NCT03705663 is a clinical study titled "Identification of the Pre-exposure Prophylaxis (PrEP) Cascade for Women.". Pre-exposure prophylaxis (PrEP) is a daily pill that greatly reduces the risk of transmission of human immunodeficiency virus (HIV), however the barriers to PrEP use for women are understudied and PrEP is underutilized by women. Partnering with the DC Department of Health and the DC Center for AIDS ...
What is the current status of trial NCT03705663?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2018-07-01. Estimated completion is 2020-04-27.
What interventions are being tested in trial NCT03705663?
The interventions under investigation include: PrEP initiation (BEHAVIORAL).
Who is sponsoring clinical trial NCT03705663?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI